id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2821205,4e7553a3-40f9-4ac5-bc4c-e2d7ff11c628,Q2,FORBES-TATE,400976792,ALTRIA CLIENT SERVICES LLC,2022,second_quarter,HCR,Issues related to flavors in Tobacco products; Conversations concerning federal appropriations policy related to FDA clarity on CBD.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-07-15T17:35:35-04:00
2821206,4e7553a3-40f9-4ac5-bc4c-e2d7ff11c628,Q2,FORBES-TATE,400976792,ALTRIA CLIENT SERVICES LLC,2022,second_quarter,TAX,Issues related to tobacco tax; Issues related to excise tax on tobacco in the HR 5376 - Build Back Better Act.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-07-15T17:35:35-04:00
2821207,4e7553a3-40f9-4ac5-bc4c-e2d7ff11c628,Q2,FORBES-TATE,400976792,ALTRIA CLIENT SERVICES LLC,2022,second_quarter,BUD,"Appropriations Issues related to H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-07-15T17:35:35-04:00
2821208,4e7553a3-40f9-4ac5-bc4c-e2d7ff11c628,Q2,FORBES-TATE,400976792,ALTRIA CLIENT SERVICES LLC,2022,second_quarter,FOO,Conversations concerning federal appropriations policy related to FDA clarity on CBD.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-07-15T17:35:35-04:00
2821209,4e7553a3-40f9-4ac5-bc4c-e2d7ff11c628,Q2,FORBES-TATE,400976792,ALTRIA CLIENT SERVICES LLC,2022,second_quarter,SCI,Conversations concerning federal appropriations policy related to FDA clarity on CBD.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-07-15T17:35:35-04:00
2821210,4e7553a3-40f9-4ac5-bc4c-e2d7ff11c628,Q2,FORBES-TATE,400976792,ALTRIA CLIENT SERVICES LLC,2022,second_quarter,GOV,Conversations concerning federal appropriations policy related to FDA clarity on CBD.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-07-15T17:35:35-04:00